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Background. Empirical therapy with antisecretory agents like PPIs and H2RAs has long been the traditional approach in the initial
management of uninvestigated dyspepsia. Aim. The objective of the study was to examine relief of dyspepsia with lafutidine, a
second-generation H2-RA, and rabeprazole and to compare their eﬃcacy. Methods. This was a randomized, open, comparative
trial in adult uninvestigated dyspeptic patients, who had at least moderate severity of symptoms, deﬁned as a score of ≥4o na
7-point global overall symptom (GOS) scale, and were randomized to receive once daily either lafutidine 10mg or rabeprazole
20mg for 4 weeks. Results. A total of 236 patients were enrolled, out of which 194 patients were included in the analysis.At the end
of week 4, a signiﬁcant diﬀerence was observed for symptom relief (lafutidine 89.90% versus rabeprazole 65.26%, P<. 01) and
symptom resolution (lafutidine 70.71% versus rabeprazole 25.26%, P<. 01). Both the drugs were well tolerated. Conclusion.B o t h
lafutidine and rabeprazole provide symptom relief in patients with heartburn-dominant uninvestigated dyspepsia. The present
study conﬁrms the appropriateness of lafutidine as an empiric treatment and superior eﬃcacy for primary care practice patients
with dyspepsia.
1.Introduction
Dyspepsia is believed to be common worldwide [1]. In the
Indian population,dyspepsia wasfoundtobemorecommon
in subjects aged 40 years or younger [2]. It is more prevalent
in the metros, where it is reported by almost one-third of the
population [3].
The Canadian Dyspepsia Working Group deﬁnition
states that “Dyspepsia is a symptom complex of epigastric pain
or discomfort thought to originate in the upper gastrointestinal
tract, and it may include any of the following symptoms: heart-
burn, acid regurgitation, excessive burping/belching, increased
abdominal bloating, nausea, feeling of abnormal or slow diges-
tion, or early satiety”[ 4]. Patients with dyspeptic symptoms
who are not candidates for early endoscopy are termed
“uninvestigated dyspeptics” [5].
The American College of Gastroenterology Guidelines,
and the NICE guidelines from UK, for the management of
dyspepsia have among others stated two commonly used
strategies, namelytestandtreatstrategyandacidsuppression
therapy [6, 7]. For those in whom the predominant symp-
toms are thought to be acid related, such as epigastric pain
or burning, a trial of acid suppression is often recommended
if the patient is under 45–55 years of age without obvious
organic disease [8].
Empirical therapy with antacids, antisecretory, and
prokinetic agents has long been the traditional approach
for most primary care physicians in the initial management
of patients with uninvestigated dyspepsia [9]. Since their
introduction in the mid-1970s, H2-RA have gained wide
acceptance as antisecretory drugs with proven eﬃcacy in
the treatment of peptic ulcers and gastro-oesophageal reﬂux
disease. Therearecurrentlyfourdrugsinthiscategoryinuse:
cimetidine, ranitidine, famotidine, and nizatidine [10].
Lafutidine was developed as a second-generation H2-RA
with an increased action on the gastric mucosal defensive2 Gastroenterology Research and Practice
capacity. It has been reported that the gastroprotective
eﬀect of lafutidine is independent of its acid antisecretory
activity [11]. In addition to being a potent H2 receptors
antagonist [12], lafutidine also activates capsaicin-sensitive
aﬀerent neurons and stimulates the release of calcitonin
gene-related peptide (CGRP), which inhibits acid secretion
and stimulates mucosal blood ﬂow [13–15]. The gastro
protective action of lafutidine includes increase in mucin
biosynthesis via stimulation of nitric oxide production [11,
16], increasing the thickness of the surface mucus gel
layer [17], and maintaining gastric mucosal blood ﬂow and
bicarbonate response [18]. Lafutidine has been elaborately
studied internationally in various indications like gastritis,
and gastric and peptic ulcer, while recent focus has also
shifted to its use in gastroesophageal reﬂux disorder (GERD)
[19–23].
The objective of the present study was to compare the
eﬃcacy of lafutidine and rabeprazole in the management
of heartburn-dominant uninvestigated dyspepsia in Indian
primary care practice.
2.Methods
Thecurrentstudy(studyno.:Emc/GASTR/LAFUT/12/2008)
was a prospective, multicentric study, carried out at 5 centers
in India. The study was conducted in accordance with the
Declaration of Helsinki and its subsequent amendments and
in compliance with the ICH-GCP (International Conference
on Harmonization-Good Clinical Practice) Guidelines. All
patientswere required togive theirwritteninformed consent
before entering into the study. The protocol was approved
by “Jagruti-Independent Ethics Committee”, Mumbai, India,
for each investigational centre in August 2009.
2.1. Patients. Patients aged 18 years or older were eligible
if they had a minimum of 1-month history of dyspepsia
(including symptoms of heartburn and/or epigastric pain
and/or bloating) with at least one moderate-to-severe symp-
tom (score ≥4 on a 7-point global overall symptom (GOS)
scale) on at least three of the 7 days before randomization.
The main exclusion criteria were presence of alarm features
(unintentional weight loss, persistent vomiting, dysphagia,
haematemesis, melaena, fever, jaundice, or anaemia), irrita-
blebowelsyndromeorseriousconcomitantdisease,previous
history of gastrointestinal disease (including peptic ulcers,
malignancy, oesophageal dysmotility, a previous endoscopic
or radiological diagnosis of GERD, and Barrett’s oesopha-
gus), recent gastrointestinal surgery, that is, within 30 days
(except appendectomy, colonic resection, and cholecystec-
tomy),treatmentwith nonsteroidalanti-inﬂammatory drugs
(NSAIDs), acetylsalicylic acid (>325mg/day), H2-RAs, PPIs,
prokinetic agents, misoprostol, or sucralfate 15 days prior to
enrollment, and a known history of hypersensitivity to the
study medications.
Patients who had previously been included or who had
participated in any other clinical trial within one month
before enrollment into the current study were excluded.
Women who were pregnant, lactating, or who desire to
become pregnant during the study were not enrolled.
Patients who were drug or alcohol abusers or suﬀering from
any other condition associated with poor compliance were
excluded from the study.
2.2. Study Design. The current study was a randomized,
comparative-controlled clinicaltrial, wherein a targetsample
size of at least 200 patients with clinical signs and symptoms
of dyspepsia were to be enrolled. Each investigator of the
ﬁve participating centers was to enroll 50 patients. Based
on the inclusion/exclusion criteria as stated in the protocol,
the participant was considered eligible for participating in
the study by the investigator. Once enrolled, the patients
received treatment for a period of four weeks (28 days) with
either lafutidine or rabeprazole, as per the two-treatment
computer-generated randomization sequence, using WIN-
PEPI Version 8.6. Each patient was supplied with the med-
ication (lafutidine or rabeprazole) which would suﬃce for
the treatment duration of 4 weeks. The patient’s medication
supply was divided into two parts, administered at the time
of enrollment and on day 14 (after week 2). Thus, each
investigator was provided with medication supply for 50
patients: two sealed, tamperproof, labeled, plastic containers
containing 14 tablets of lafutidine or rabeprazole for each
patient. During this study period, the patients were assessed
for the clinical signs and symptoms and the response to
the treatment after week 2 (day 14) and week 4 (day
28). Laboratory assessment was performed at the time of
enrollment and at the end of the study.
2.3. Treatment. Patients received the study medications as
per the randomization chart for duration of 28 days. The
dosageregimenoftheinvestigational drugwas onelafutidine
10mg tablet (manufactured by: Emcure Pharmaceuticals
Ltd; Batch no: FD/388/09)to be takenonce daily for 28 days,
while that of the control group was one rabeprazole 20mg
tablet(manufactured by:Windlas BiotechLimited;Batch no:
ZYB09003) to be taken once daily for 28 days. Adherence
t ot h ec o m p l i a n c ef o rm e d i c a t i ons was calculated using pill
count of returned medications after two and four weeks of
treatment.
2.4. Assessments. Patients were asked to indicate the overall
severity of their dyspepsia symptoms during the previous
two days using the validated 7-point GOS ccale: (1) no
problem, (2) minimal problem (can be easily ignored
without eﬀort), (3) mild problem (can be ignored with
eﬀort), (4) moderate problem (cannot be ignored but does
not inﬂuence my daily activities), (5) moderately severe
problem(cannot be ignored and occasionally limits my daily
activities), (6) severe problem (cannot be ignored and often
limits my concentration on daily activities), and (7) very
severe problem(cannot be ignored, markedly limits my daily
activities and often requires rest).
A patient reporting at least moderate severity (score ≥4)
for an individual symptom was considered to be symp-
tomatic for that speciﬁc symptom. Reassessment was per-
formed at the end of second week (day 14) and fourth week
(day 28).Gastroenterology Research and Practice 3
N = 236: screened
N = 202: randomized
Week 4
N = 99: completed the study
Day 0
N = 101: received rabeprazole
Day 0
N = 101: received lafutidine
N = 34: excluded
Reason: not meeting inclusion
criteria
Week 2
N = 98: came for followup visit
N = 3: lost to followup
Week 2
N = 99: came for followup visit
N = 2: Lost to followup
Week 4
N = 95: completed the study
N = 3: lost to followup
Figure 1: CONSORT ﬂow diagram showing the number of patients enrolled in the study randomized to each treatment group and reasons
for discontinuation.
The “overall treatment evaluation” (OTE) assessed the
patient’s perspective on symptom relief on a 6-point Likert
scale ((1) the treatment made me a lot worse; (2) the
treatment made me slightly worse; (3) the treatment made
no change to my symptoms; (4) the treatment made me
slightlybetter; (5)the treatment made me alotbetter; (6)the
treatment completely relieved my symptoms). The “overall
patient satisfaction survey” (OPSS)evaluatedpatient satisfac-
tionwithtreatment using a6-point Likertscaleranging from
completelysatisﬁed (1) tocompletelydissatisﬁed (6).Finally,
thefrequencyandseverityofadverseeventswereevaluatedat
eachvisitwhileclinicallyimportantchangesinthelaboratory
data during the study were assessed.
2.5. Study Outcome. The primary study outcome was deter-
mination of the “symptom relief,” that is, the proportion of
the patients achieving a score of GOS ≤ 2 for epigastric pain,
heartburn, and abdominal bloating after two and four weeks
of treatment.
The secondary outcomes included the determination of
the resolution of the symptoms of dyspepsia, that is, the
proportion of the patients achieving “symptom resolution”
(GOS = 1) and “symptom improvement” (ΔGOS ≥ 2) for
epigastric pain, heartburn, and abdominal bloating after 2
and 4 weeks of treatment.
The proportions of the patients for the analysis of
patient’s perspective on symptom relief with a score of ≥4
on the 6-point Likert scale at the end of week 2 and week 4
wereevaluated.Theproportionofthepatientswithascoreof
≤3 on the 6-point Likert scale for overall patient satisfaction
survey (OPSS) was also assessed and compared at the end of
the study.
2.6. Statistical Analysis. The change in severity of individual
symptoms between the visits in each treatment group
was compared by Wilcoxon rank sum test. A compara-
tive evaluation for the mean score reduction between the
two groups was performed by Mann-Whitney U-test. The
proportions of patients with symptom relief, resolution,
and improvement over the 4-week treatment period were
reported as “percentage” along with their “95% conﬁdence
interval” (CI), and the comparison between the treat-
ment groups was performed using Fisher’s exact test. The
treatment assessment results reported by the patients were
summarized in frequency tables by treatment groups. The
comparison of the mean scores of treatment assessment
results was performed by Mann-Whitney U-test. All data
are presented as mean ± standard deviation (SD) unless
stated otherwise. P value less than .05 was considered
signiﬁcant.
3.Results
3.1. Patient Characteristics and Disposition. Of the 236
patients cumulatively enrolled by the 5 centres, 194 patients
completed the study, of which 99 patients received lafutidine
while 95 of them received rabeprazole. Figure 1 shows the
consolidated standards of reporting trials (CONSORT) ﬂow
chart of patients throughout the study. Thus, the study
population comprised 194 patients who were evaluated for
resolution of clinical symptoms of dyspepsia and for the
incidence of adverse events. Patients were enrolled over
a 4-month period, from August 2009 to November 2009.
The study was completed by ﬁrst week of December 2009.
Baseline demographic data are shown in Table 1.I tw a s4 Gastroenterology Research and Practice
Table 1: Demographic summary.
Lafutidine (N = 99) Rabeprazole (N = 95)
Gender
Males, n (%) 62 (62.63) 53 (53.54)
Females, n (%) 37 (37.37) 41 (41.41)
Age (years)
Mean ± SD 39.24 ± 11.82 40.47 ± 12.13
Median 38 38
Range 18–66 20–74
Weight (Kg)
Mean ± SD 59.48 ± 10.36 61.43 ± 9.76
Median 59 60.5
Range 38–85 40–90
Symptoms (score ≥4 at baseline)
Epigastric pain, n (%) 89 (89.89) 80 (84.21)
Heartburn, n (%) 96 (96.96) 93 (97.89)
Abdominal pain, n (%) 90 (90.9) 80 (84.21)
observed that obesity was uncommon in the group of
patients enrolled in this study.
In the study population, most of the patients suﬀered
from one or more symptoms. The proportion of patients
with moderate to severe dyspepsia symptoms (score ≥4o n
a 7-point global overall symptom (GOS) scale) is reported
in Table 1. The overall prevalence of all the 3 symptoms with
as c o r e≥4 on GOS scale was found in 81 (81.81%) and 70
(73.68%)ofthe patientsin lafutidine and rabeprazole group,
respectively.
Adherence to therapy over the 4-week duration was
excellent as 100% and 98.94% of the patients took the
medication as per the dosage regimen in the lafutidine and
rabeprazole groups, respectively. Noneofthe patientsmissed
the dose for more than two successive days anytime during
the study period.
3.2.OverallSymptomAssessment. Theproportionofpatients
achieving symptom relief, symptom resolution, and symp-
tom improvement for the overall severity of their dyspepsia
symptoms in each treatment group is tabulated in Table 2.
At the end of week 2, the proportion of patients achieving
symptom relief (GOS ≤ 2) and symptom resolution (GOS =
1) between the two treatment groups was not signiﬁcant. By
the end of week 4, the proportion of patients with symptom
relief and symptom resolution was signiﬁcantly higher in
patients in lafutidine group than rabeprazole group. In
terms ofsymptom improvement (ΔGOS ≥ 2), lafutidine and
rabeprazole groups were not signiﬁcantly diﬀerent (Table 2).
3.3. Response by Individual Symptom. Ap a t i e n tw a sc o n s i d -
ered to be symptomatic for an individual symptom if that
symptom was reported to be at least moderate (score ≥4) in
severity at baseline. Patients in the lafutidine group reported
a better improvement in epigastric pain, heartburn, as well
as abdominal bloating as compared to rabeprazole group,
which was statistically signiﬁcant, after 4 weeks of treatment
(Figures 2 and 3).
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Figure 2: Proportion of patients who reported symptom relief for
each individual symptom from baseline. The number of patients
listed foreach symptomisthe number ofpatients thatreported that
s y m p t o mw i t haG O Ss c o r e≥4 at baseline.∗P<. 01 between the two
treatment groups at week 4.
At baseline, the mean score for each symptom did not
diﬀer signiﬁcantly between the two treatment groups. A
signiﬁcant reduction in the mean score for each symptom
from the mean baseline score at week 2 and week 4 was
observed in both lafutidine as well as rabeprazole group
(Table 3).
3.4. Patient’s Assessment of the Treatment. In the “overall
treatment evaluation” (OTE) assessing the patient’s perspec-
tive on symptom relief, lafutidine was better than rabepra-
zole. At the end of week 4, among the total patients in each
group, a score of 4 and above (slightly better to completely
relieved my symptoms) was reported by 95.96% and 87.37%
in the lafutidine and rabeprazole group, respectively. At the
end of the study, 74.75% of the lafutidine-treated patients
stated that the treatment had completely relieved theirGastroenterology Research and Practice 5
Table 2: Proportion of patients achieving symptom relief (GOS ≤ 2), symptom resolution (GOS = 1), and symptom improvement
(ΔGOS ≥ 2).
Lafutidine (N = 99)
N (%) (95% CI)
Rabeprazole (N = 95)
N (%) (95% CI) Diﬀerence (95% CI) P value
Symptom relief
(GOS ≤ 2)
Week 2 15 (15.15) (8.74 to 23.76) 13 (13.68) (7.49 to 22.26) 1.50% (−9.40 to 12.40) .840
Week 4 89 (89.90) (82.21 to 95.05) 62 (65.26) (54.80 to 74.74) 24.60% (12.30 to 36.90) <.001
Symptom resolution
(GOS = 1)
Week 2 1 (1.01) (0.03 to 5.50) 5 (5.26) (1.73 to 11.86) −4.30% (−10.20 to 1.70) .113
Week 4 70 (70.71) (60.71 to 79.43) 24 (25.26) (16.91 to 35.22) 45.40% (31.90 to 59.00) <.001
Symptom improvement
(ΔGOS ≥ 2)
Week 2 65 (65.66) (55.44 to 74.91) 51 (53.68) (43.15 to 63.98) 12.00% (−2.80 to 26.70) .107
Week 4 91 (91.92) (84.70 to 96.45) 85 (89.47) (81.49 to 94.84) 2.40% (−6.80 to 11.70) .626
Table 3: Symptom score (Mean ± SD) at baseline and after 2 and 4 weeks.
Lafutidine Rabeprazole P value for diﬀerence between treatments
Mean score ± S.D. (N = 99) Mean score ± S.D. (N = 95)
Epigastric pain
Baseline 4.86 ± 1.19 4.87 ± 1.42 NS
Week 2 2.86 ± 0.71∗ 3.17 ± 0.96∗ .002
Week 4 1.28 ± 0.74∗ 1.91 ± 1.07∗ <.0001
Heartburn
Baseline 5.07 ± 0.99 5.13 ± 0.91 NS
Week 2 2.71 ± 0.70∗ 2.98 ± 0.94∗ .0224
Week 4 1.28 ± 0.71∗ 2.04 ± 1.03∗ <.0001
Abdominal bloating
Baseline 4.92 ± 1.08 4.97 ± 1.25 NS
Week 2 2.60 ± 0.74∗ 2.97 ± 1.06∗ .0075
Week 4 1.36 ± 0.83∗ 1.95 ± 1.00∗ <.0001
∗P Value less than .001 versus baseline, within the group.
NS: not signiﬁcant (P>. 05).
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Figure 3:Proportionofpatients whoreported symptomresolution
foreachindividualsymptomfrombaseline.Thenumber ofpatients
listedforeach symptom isthenumber ofpatientsthatreported that
symptom with a GOS score ≥4 at baseline.∗P<. 01 between the two
treatment groups at week 4.
symptoms, compared to 32.63% of the rabeprazole-treated
patients(Table 4). The meanscore ofpatient’sperspective on
symptom relief was signiﬁcantly higher in lafutidine group
(5.52 ± 0.95 versus 4.83 ± 1.05 in rabeprazole group, P<
.0001).
At the 4-week assessment, when patients were asked
to rate the overall satisfaction of their current treatment,
88.89% and 65.26% in the lafutidine and rabeprazole group
respectively reported a score of 3 or less (quite satisﬁed to
very satisﬁed). The satisfaction survey response reported by
the patients is shown in Figure 4. The mean score of overall
patient satisfaction was signiﬁcantly higher in lafutidine
group at the end of the study (1.57±1.1v er s us2.59±1.51in
Rabeprazole group, P<. 0001).
3.5. Adverse Events. Both the treatment groups were found
to be safe and well tolerated. The frequency of adverse events
reported was similar in both treatment arms although the
type of adverse event reported in each treatment group
was diﬀerent. None of the adverse events experienced by
the subjects during this study were judged as serious. In
lafutidine group, one patient reported constipation which
was rated “moderate” in severity at the end of week 2 and 4
visit, while another patient reported it only at the end of
week 4 which was rated as “mild” in severity. Diarrhea was
reported by 1 patient by week 4 in the lafutidine group
which was rated as “mild” in severity. In case of rabeprazole
group, 3 patients reported headache as an adverse event at6 Gastroenterology Research and Practice
Table 4: Frequency distribution of “patient’s perspective on symptom relief” survey responses.
At the end of week 2 At the end of week 4
Patient’s perspective on
symptom relief of the treatment
Lafutidine Rabeprazole Lafutidine Rabeprazole
(n = 99) (n = 95) (n = 99) (n = 95)
n (%) n (%) n (%) n (%)
Made me a lot worse 0 (0.00) 0 (0.00) 1 (1.01) 0 (0.00)
Made me slightly worse 0 (0.00) 0 (0.00) 0 (0.00) 1 (1.05)
Made no change to my
symptoms
4 (4.04) 13 (13.68) 3 (3.03) 11 (11.58)
Made me slightly better 30 (30.30) 45 (47.37) 13 (13.13) 22 (23.16)
Made me a lot better 62 (62.63) 33 (34.74) 8 (8.08) 30 (31.58)
Completely relieved my
symptoms
3 (3.03) 4 (4.21) 74 (74.75) 31 (32.63)
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Figure 4:Frequency distribution ofsatisfaction surveyresponses at
the end of the treatment phase.
the end of week 2 which was rated as “mild”i ns e v e r i t y .
Thus, the overall incidence of adverse events reported were
headache (2.65%) in rabeprazole group and constipation
(1.73%) and diarrhoea (0.86%) in lafutidine group. There
were no clinically relevant laboratory abnormalities in either
treatment group.
4.Discussion
Dyspepsia is a common problem encountered in general
practice. There have been many dyspepsia management
strategies and guidelines published in recent years. The
British Society of Gastroenterology (BSG) Dyspepsia Man-
agement Guidelines state that it is acceptable to initiate
a single course of treatment with an antisecretory agent,
for 2 to 4 weeks, in patients under the age of 45 years
who are experiencing troublesome dyspepsia but exhibit
no alarm symptoms. Endoscopy is not recommended in
this group of patients without evidence of the presence
of Helicobacter pylori together with persistent symptoms.
Treatment without investigation is, therefore, appropriate in
many cases [24].
The present study focuses on uninvestigated dyspep-
tics, that is, patients with dyspepsia symptoms who are
not candidates for early endoscopy. Endoscopy was not
performed at enrolment in the present study; although
it would have allowed risk stratiﬁcation with respect to
oesophagitis severity and H. pylori infection, it would also
have introduced the potential for bias in a study intended
to assess symptom response to empiric therapy in a primary
care environment.
The prevalence of uninvestigated dyspepsia in India
has been reported to be 30.4% [25], while in another
study, the ethnic prevalence of esophagitis was 8.5% among
Indians [26]. Helicobacter pylori infection is common in
the Indian subcontinent. Exposure occurs in childhood and
approximately80%ofadultshavebeeninfectedatsome time
[27].
The GOS scale used in this study is a validated outcome
measure and has been used successfully in the CADET
(Canadian Adult Dyspepsia Empiric Treatment) Clinical
Trials Program. In the validation of the GOS study, it has
been shown that a change in GOS from ≥4t o≤2i sr a t e d
as clinically important by patients [28].
In this study, both rabeprazole and lafutidine showed
positive eﬀects on the symptoms of epigastric pain, heart-
burn, and abdominal bloating. A statistically nonsigniﬁcant
diﬀerence in response was observed for both the treatments
at the endofsecond week; however, at week 4, thediﬀerences
were statistically signiﬁcant. No serious or life-threatening
adverse events were observed in either treatment groups
and the absence of any signiﬁcant change in the laboratory
parameters conﬁrms the safety of both the drugs.
Meta-analysis evaluating the eﬃcacy of H2-RA in func-
tional (nonulcer) dyspepsia has shown that H2-RAs are
superior to placebo [12]. Proton pump inhibitors (PPIs) are
more potent inhibitors of gastric acid secretion than the ﬁrst
generation H2-RAs [29]. Most clinicians acknowledge the
advantage of PPIs over H2-RAs, because the former exert
stronger and longer acid suppression than the latter [30].
Clinical trials comparing a PPI (omeprazole and lansopra-
zole) and H2-RA (ranitidine and cimetidine) demonstrates
superiority of PPI over H2-RA (ranitidine) in dyspepsia
[10, 24, 31].Gastroenterology Research and Practice 7
Thereareonlyafewstudiescurrentlyavailableevaluating
the treatment for uninvestigated dyspepsia in comparisons
to those for the treatment of functional dyspepsia or GERD.
Empirical treatment of dyspepsia with PPI leads to an
acceptable symptom relief in 54%–65% of the patients
compared with 33%–53% with placebo [32]. Armstrong
et al. reported resolution of only heartburn in 36.2% of
the patients treated with omeprazole 20mg a day [31]. In
another study, an overall resolution of all the dyspepsia
symptoms was observed 22.9% of the patients treated with
esomeprazole 40mg once daily [28]. In the current study,
symptom resolution for all the dyspepsia symptoms was
observed in 25.26% rabeprazole-treated patients, while in
lafutidine-treated patients, this proportion was signiﬁcantly
higher, 70.71%. The better eﬃcacy of lafutidine seen in this
study can be attributed to the novel mechanism of action of
lafutidine which includes gastric mucosal protective action
mediated by capsaicin-sensitive aﬀerent neurons, in addition
to a potent antisecretory eﬀect.
In conclusion, the current study shows that both lafuti-
dine and rabeprazole are eﬀective in relieving the symptoms
of dyspepsia. Therapy with lafutidine, a second-generation
H2-RA, may be more useful than rabeprazole in relieving
symptoms of heartburn-dominant uninvestigated dyspepsia.
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